ClinicalTrials.gg
RecruitingNCT06546670Updated Oct 27, 2026

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

A Phase 1/2 interventional study of ITU512 and Placebo in Sickle Cell Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 14 sites in 3 countries. Open to participants aged 12 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 27, 2026First site in BrazilStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Anemia, Sickle Cell by Novartis — 3 open to participants now, 5 under way, 2 of them phase 3. Anemia, Sickle Cell · Novartis.

Planned enrollment
7th of 16
161 · median 135
Started
2024
with 2 others
Phase 1/2
Only one
of the 25
Registered
22nd of 25
by date

Among the 25 studies in Anemia, Sickle Cell by Novartis, this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 22nd registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

3 of the 25 studies in Anemia, Sickle Cell by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Anemia, Sickle Cell by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).

Read the detailed description

This is a global, randomized, Phase I/II study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary food effect of single-agent ITU512 in adult healthy participants, and safety, tolerability, PK, PD, and efficacy of ITU512 in adolescent and adult patients with sickle cell disease (SCD). The study consists of a first-in-human Phase I study (Part 1) in healthy participants, and a Phase II study (Part 2) in patients with SCD.

Part 1 will comprise of Part 1A, Part 1B, and Part 1C. Part 2 will include Part 2A and 2B and may also include an extension part (Part 2C).

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • ITU512
  • Low molecular weight
  • Small molecule
  • Sickle cell disease
04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Part 1 (Healthy participants)

  • Healthy male participants and female participants of non- between 18-55 years of age
  • In good health as determined by the investigator's assessment of medical history, physical examination, vital signs, , and laboratory tests
  • Participants must weigh at least 50 kg at screening and first baseline (admission) and must have a (BMI) within the range of 18.0-32.0 kg/m2 inclusive.

Part 2 (Sickle Cell Disease)

- Male and female participants with a diagnosis of sickle cell disease

Key Exclusion Criteria:

Part 1 (Healthy participants)

  • ≥ 450 msec (as a mean value of triplicates)
  • History of arrhythmias
  • History of significant illness which has not resolved within two (2) weeks prior to initial dosing
  • Women of child-bearing potential (WOCBP)

Part 2 (Sickle Cell Disease)

  • Current use of hydroxyurea/hydroxycarbamide (HU/HC)
  • QTcF ≥ 450 msec (as a mean value of triplicates)
  • History of arrhythmias

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
161 participants (estimated)

Study arms

  • Experimental
    Part 1A

    Part 1A in healthy participants

    Drug: ITU512 · Drug: Placebo

  • Experimental
    Part 1B

    Part 1B in healthy participants

    Drug: ITU512 · Drug: Placebo

  • Experimental
    Part 1C

    Part 1C in healthy participants

    Drug: ITU512

  • Experimental
    Part 2A

    Part 2A in patients with sickle cell disease

    Drug: ITU512 · Drug: Placebo

  • Experimental
    Part 2B

    Part 2B in patients with sickle cell disease

    Drug: ITU512 · Drug: Placebo

  • Experimental
    Part 2C

    Optional extension in patients with sickle cell disease

    Drug: ITU512

Interventions

  • DrugITU512

    ITU512 is an investigational, oral, low molecular weight (LMW) compound.

  • DrugPlacebo

    An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.

06

What researchers measure

Primary outcomes

  1. Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs

    Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: Up to approximately 60 days

  2. Part 1A, Part 1B , Part 1C: Dose discontinued due to AE

    Number of participants with dose discontinuation due to AEs

    Time frame: Up to 30 days

  3. Part 2A, Part 2B: Incidence of AEs and SAEs

    Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

    Time frame: Up to 5 months

  4. Part 2A, Part 2B: Dose interruptions and reductions

    Number of participants with dose interruptions or reductions of ITU512

    Time frame: Up to 4 months

  5. Part 2A, Part 2B: Dose intensity

    Dose intensity of ITU512 is computed as the ratio of actual cumulative dose received and actual duration of exposure

    Time frame: Up to 4 months

  6. Part 2B: Fetal hemoglobin (HbF)%

    Assessment of fetal hemoglobin expression by measuring fetal hemoglobin (HbF)% by high-performance liquid chromatography (HPLC) assay

    Time frame: Month 4

Secondary outcomes

  1. Part 1A, Part 1B: Area under the plasma concentration-time curve (AUC) of ITU512

    Pharmacokinetic (PK) parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)

  2. Part 1A, Part 1B: Maximum plasma concentration (Cmax) of ITU512

    PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)

  3. Part 1A, Part 1B: Time to maximum plasma concentration (Tmax) of ITU512

    PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)

  4. Part 1A, Part 1B: Renal clearance (CLr)

    PK parameters calculated based on ITU512 urine concentrations by non-compartmental methods. The renal clearance (CLr) may be determined based on AUC and amount of drug excreted into urine (Ae) available for the same time period.

    Time frame: From pre-dose up to 48 hours post-dose on Day 1 (Part 1A) and from pre-dose up to 24 hours post-dose on Day 1 and Day 10 (Part 1B)

  5. Part 2A, Part 2B: Plasma concentrations of ITU512

    ITU512 concentration in plasma determined in non-placebo treated participants by a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method

    Time frame: From pre-dose up to 4, 6 or 8 hours post-dose on Day 1 at Month 1 and Month 2

  6. Part 2A, Part 2B: Urine concentrations of ITU512

    ITU512 concentration in urine determined in non-placebo treated participants by a LC-MS/MS method

    Time frame: From pre-dose up to 4 or 8 hours post-dose on Day 1 at Month 1

  7. Part 2A: Fetal hemoglobin (HbF)%

    Assessment of fetal hemoglobin expression by measuring fetal hemoglobin (HbF)% by HPLC assay

    Time frame: Up to 4 months

  8. Part 2A, Part 2B: Change from baseline in total hemoglobin (Hb)

    Change from baseline in total hemoglobin (Hb) over time measured in blood samples

    Time frame: Baseline, up to 4 months

  9. Part 1A, Part 1B, Part 2A, Part 2B: Change from baseline in Fridericia- corrected Holter QT interval (QTcF)

    Real-time 12-lead safety ECGs will be locally collected and evaluated. Change from baseline in QTcF with respect to PK parameters and/or ITU512 concentrations will be assessed

    Time frame: Up to 4 months

  10. Part 1C: Area under the plasma concentration-time curve from time 0 up to the time of the last quantifiable concentration (AUClast) of ITU512

    PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose

  11. Part 1C: Area under the plasma concentration-time curve from time 0 up to infinity (AUCinf) of ITU512

    PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose

  12. Part 1C: Maximum plasma concentration (Cmax) of ITU512

    PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose

  13. Part 1C: Time to maximum plasma concentration (Tmax) of ITU512

    PK parameters calculated based on ITU512 plasma concentrations by non-compartmental methods

    Time frame: From pre-dose up to 144 hours post-dose

07

Study locations

13 of 14 sites recruiting
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
    • Emily Burke · Contacteduke@uabmc.edu · +1 205 801 3411
    • Julie Kanter-Washko · Principal investigator
  • Quotient Sciences Sea View
    Miami, Florida 33126, United States
    Completed

    Not enrolling at this site.

  • Boston Childrens Hospital
    Boston, Massachusetts 02215, United States
    Recruiting
  • Icahn School Of Med At Mount Sinai
    New York, New York 10029, United States
    Recruiting
  • Levine Cancer Insitute Carolinas Healthcare System
    Charlotte, North Carolina 28204, United States
    Recruiting
  • East Carolina University
    Greenville, North Carolina 27858, United States
    Recruiting
  • Childrens Hospital Of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Avi Patel · Contactpatela67@chop.edu · +1 215 590 9959
    • Alexis A Thompson · Principal investigator
  • Lifespan
    Providence, Rhode Island 02903, United States
    Recruiting
  • UT Health Science Center
    Houston, Texas 77030, United States
    Recruiting
  • Novartis Investigative Site
    Ribeirão Preto, São Paulo 14048-900, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 01232-010, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, 05403-000, Brazil
    Recruiting
  • Novartis Investigative Site
    Ankara, Sihhiye Altindag 06230, Turkey (Türkiye)
    Recruiting
  • Novartis Investigative Site
    Adana, Yuregir 01250, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2028, 44 months after the start.

Of 37 phase 1/2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 222. This study's planned 44 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2030 → May 2030, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Aug 9, 2024
StartActual
Aug 15, 2024
Primary completionEst.
May 1, 2028
CompletionEst.
May 27, 2030was Mar 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed — first site in Brazil
Show 5 added (3 Brazil, 1 United States, 1 Turkey (Türkiye))
  • Icahn School Of Med At Mount Sinai · New York, United States
  • Novartis Investigative Site · Ribeirão Preto, Brazil
  • Novartis Investigative Site · São Paulo, Brazil
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
  • Novartis Investigative Site · São Paulo, Brazil
Show 1 removed
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
across 2 updates, Oct 9, 2026 – Oct 27, 2026
Study completion
Mar 19, 2030→May 27, 2030
Oct 20, 2026
Show all 3 updates
  1. Oct 27, 2026
    1 site added
    Show site
    • Novartis Investigative Site · São Paulo, Brazil
  2. Oct 20, 2026
    Study completion Mar 19, 2030→May 27, 2030
  3. Oct 9, 2026
    4 sites added, 1 site removed — first site in Brazil
    Show 4 added (2 Brazil, 1 United States, 1 Turkey (Türkiye))
    • Icahn School Of Med At Mount Sinai · New York, United States
    • Novartis Investigative Site · Ribeirão Preto, Brazil
    • Novartis Investigative Site · São Paulo, Brazil
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06546670
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Aug 15, 2024
Primary completion
May 1, 2028 (estimated)
Completion
May 27, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion